Skip to Content
Merck
All Photos(1)

Key Documents

421M-1

Sigma-Aldrich

p21WAF1 (DCS-60.2) Mouse Monoclonal Antibody

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

100
500

conjugate

unconjugated

antibody form

diluted ascites fluid

antibody product type

primary antibodies

clone

DCS-60.2, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (421M-14)
vial of 0.5 mL concentrate (421M-15)
bottle of 1.0 mL predilute (421M-17)
vial of 1.0 mL concentrate (421M-16)
bottle of 7.0 mL predilute (421M-18)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200

isotype

IgG2a

control

colon

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

Gene Information

human ... CDKN1A(1026)

General description

p21 is a nuclear 21 kD protein, a product of the WAF1/CIP1 gene. It is a cyclin-dependent kinase inhibitor 1A (p21, Cip1), also known as CDKN1A, which in humans is encoded by the CDKN1A gene located on chromosome (6p21.2). It is a constituent of a large complex of nuclear proteins, including cyclins, cyclin dependent kinases, and PCNA. Cell cycle progression is regulated by cyclins and their cognate Cdks. p21 inhibits the activity of each member of the cyclin/Cdk family. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).

Quality


IVD
IVD
IVD
RUO

Linkage

p21WAF1 Positive Control Slides, Product No. 421S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Ikeguchi et al.
Digestive diseases and sciences, 43(5), 964-970 (1998-05-20)
To evaluate whether the expression of p53 and that of p21 are independent prognostic factors in patients with advanced gastric cancer, we investigated clinicopathological factors and the expression of p53 and p21 in 158 patients with gastric cancer that had
Jinyoung Yoo et al.
Journal of Korean medical science, 22(2), 318-325 (2007-04-24)
Non-small cell lung cancers (NSCLC) vary in their biologic behavior. Recurrence and tumor-related mortality may be attributable to molecular abnormalities in primary tumors. This study evaluated such immunophenotypes with regard to cell cycle regulation and proliferation, apoptosis, and angiogenesis, to
J A DiGiuseppe et al.
The American journal of pathology, 147(4), 884-888 (1995-10-01)
The p53 tumor suppressor gene is mutated in the majority of pancreatic adenocarcinomas, and several studies have suggested that loss of p53 function may contribute to the aggressive clinical behavior of pancreas cancer. Although immunocytochemical accumulation of the p53 gene
Mi Seon Kwon et al.
Pathology, research and practice, 202(12), 849-856 (2006-11-04)
Few studies have focused on the correlation between p21 expression and survival for patients with non-small cell lung carcinoma (NSCLC), and the results are not consistent. We investigated the expression of p21 in 90 cases of NSCLC to evaluate the
Motohiko Tamura et al.
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 13(1), 9-14 (2007-03-30)
The prognostic value of p21 protein expression in lung cancer patients has been assessed. However, its significance in those with pulmonary squamous cell carcinoma following induction chemotherapy (IC) remains unclear. We studied on patients who did or did not undergo
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service